Could High Glucose Drain Muscle NAD+? The Evidence

A taste receptor in skeletal muscle may respond to high glucose by accelerating NAD+ consumption. If that finding translates from mice to people, blood-sugar control and exercise could protect the same cellular fuel pool from opposite directions: exercise raises the capacity to make NAD+, while lower glucose may reduce one route of NAD+ loss.

That is an interesting hypothesis, not a settled explanation for muscle aging. The glucose-sensing pathway has appeared in one mouse-and-cell study, at glucose concentrations consistent with marked hyperglycemia. Human research does support the broader picture: muscle NAD+ tracks with healthier aging and physical function, and exercise training increases NAMPT, the rate-limiting enzyme in NAD+ salvage synthesis. The evidence for supplements is narrower and depends heavily on who takes them.

A sweet receptor with an unexpected job

In a 2024 Nature Communications mouse study, researchers reported that the sweet-taste receptor pair TAS1R2/TAS1R3 is present in skeletal-muscle fibers. In mouse muscle cells, extracellular glucose activated signaling through ERK1/2 and PARP1, an enzyme that consumes NAD+ while adding poly(ADP-ribose) chains to proteins.

The researchers used 20 mM glucose, about 360 mg/dL, and saw lower NAD+ and higher poly(ADP-ribosyl)ation after six hours. A non-metabolizable glucose analog, 3-O-methylglucose, produced similar NAD+ depletion. That detail matters: the proposed effect did not require muscle cells to burn glucose. It appeared to come from receptor signaling.

Muscle-specific Tas1r2 knockout mice were protected from the fall in muscle NAD+ seen during refeeding. In wild-type mice, higher plasma glucose correlated with lower muscle NAD+; the reported slope was statistically significant at p=0.001 and became significantly flatter in knockout mice. Blocking TAS1R2 or PARP1/2 also prevented the cell-culture effect.

Those experiments make a coherent case for a receptor-to-PARP1 pathway in mice. They do not show that a healthy person's post-meal glucose rise drains NAD+ in muscle. The study tested 20 mM glucose, whereas typical postprandial peaks in people without diabetes are closer to 7 to 9 mM. The activation threshold between those ranges remains unknown. No published study has established functional TAS1R2 glucose sensing in human skeletal muscle, and no independent group has yet replicated the finding.

What human evidence does support

The human case begins with association, not proof of cause. A 2023 Nature Aging study found that skeletal-muscle NAD+ abundance was positively associated with healthy aging and muscle function. It supports the idea that better-functioning muscle and higher NAD+ travel together across the lifespan. It cannot tell us whether low NAD+ causes poorer function, poorer function lowers NAD+, or both reflect other features of health and activity.

Exercise has the strongest direct human evidence among the practical levers. A 2023 systematic review and meta-analysis found that exercise training significantly increased intracellular NAMPT expression in human skeletal muscle. NAMPT is the rate-limiting enzyme in the NAD+ salvage pathway, which recycles nicotinamide into NAD+. Training therefore appears to increase the machinery that can replenish NAD+, rather than merely delivering a short-lived precursor dose.

This does not prove that every workout raises muscle NAD+ by a clinically meaningful amount, nor does it establish the best exercise prescription. But it gives exercise a firmer footing than most NAD+-oriented interventions: it changes a relevant enzyme in human muscle, and it fits the observed relationship between fitness, muscle function, and NAD+ abundance.

NMN has a targeted human signal, not a universal one

A randomized trial by Yoshino et al. tested NMN in 25 prediabetic postmenopausal women. Participants took 250 mg daily for 10 weeks. Compared with placebo, NMN increased skeletal-muscle insulin sensitivity measured with a hyperinsulinemic-euglycemic clamp and increased AKT/AMPK signaling.

That is a meaningful result in a metabolically vulnerable group. It does not show that NMN prevents sarcopenia, increases strength, or raises muscle NAD+ in the general population; the trial did not use those endpoints. Its small sample, single-sex population, and focus on prediabetes also limit generalization. Still, it is more relevant to muscle metabolism than a supplement study that only measures blood metabolites.

A 2026 systematic review and meta-analysis of randomized trials reported benefits of NMN for muscle and liver function in middle-aged and older adults. The publication's available summary does not provide effect sizes, confidence intervals, or outcome-specific heterogeneity, so it cannot settle how large or consistent the muscle effects are.

NR should not be treated as interchangeable with NMN. In a 2021 study of trained people during endurance exercise, acute NR supplementation did not change muscle metabolic responses, substrate use, or NAD+-sensitive signaling. The contrast with the NMN trial could reflect compound differences, acute versus 10-week exposure, or a ceiling effect in trained participants who already have higher NAD+ synthesis capacity. It remains unresolved.

Trigonelline adds a food-based clue

Trigonelline, a compound found in coffee, can act as an NAD+ precursor. A 2024 Nature Metabolism study found lower trigonelline in sarcopenic older adults than in age-matched controls. Supplementation improved muscle function in aging models, not in a human clinical trial.

This is a useful clue, not a reason to prescribe coffee as sarcopenia treatment. The human result is observational, and the functional supplementation findings came from models of aging. Coffee remains a reasonable dietary choice for people who tolerate it, but it cannot replace resistance training, adequate protein, or medical care for diagnosed sarcopenia.

PARP1 may be part of the story, not the whole story

PARP1 is one NAD+ consumer, but it is not automatically the dominant one in aging human muscle. CD38 is another major NAD+-consuming enzyme and has been implicated in diseased muscle; sirtuins and other enzymes also use NAD+. A 2022 study of diseased muscle adds to the case that CD38 can matter substantially in pathological settings.

The mouse glucose study inferred a central role for PARP1 because a PARP1/2 inhibitor did not add further protection in Tas1r2 knockout mice. That is persuasive within that model. It does not quantify how much PARP1, CD38, sirtuins, or SARM1 contribute to NAD+ loss in older human muscle. A person with inflammation, diabetes, injury, or frailty may have a different balance of NAD+-consuming pathways than a laboratory mouse after refeeding.

What to do with this now

• Make exercise the foundation. Human meta-analytic evidence shows training raises muscle NAMPT. Resistance training and regular aerobic activity also have benefits that do not depend on any NAD+ theory.
• Manage glucose for established metabolic reasons. Avoiding persistent hyperglycemia is sensible. The claim that smaller glucose excursions preserve muscle NAD+ through TAS1R2 remains untested in humans.
• Consider NMN as conditional, not automatic. The clearest trial signal comes from prediabetic postmenopausal women taking 250 mg daily for 10 weeks. Healthy, trained people should not assume the same benefit.
• Treat coffee and trigonelline as supplementary. The sarcopenia association is intriguing, but it does not establish a treatment effect in people.

The most plausible working model is a two-sided problem: inactivity can reduce NAD+ synthesis capacity, while high glucose may increase NAD+ consumption. Exercise addresses the first side in humans. The second side is an elegant mouse mechanism waiting for a human test.

The study that would change this conversation is straightforward in principle: measure muscle NAD+ in human biopsies while testing realistic glucose exposures, glycemic interventions, and exercise, ideally across normoglycemic and prediabetic adults. Until then, the practical hierarchy is clear. Train your muscles, manage metabolic health, and regard NAD+ supplements as a targeted experiment rather than cellular insurance.